Zacks Research Has Pessimistic Outlook of GSK Q1 Earnings

GSK plc (NYSE:GSK) – Equities researchers at Zacks Research lowered their Q1 2026 earnings estimates for GSK in a report issued on Wednesday, December 11th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $1.12 for the quarter, down from their prior forecast of $1.14. The consensus estimate for GSK’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK’s Q2 2026 earnings at $1.12 EPS and Q3 2026 earnings at $1.52 EPS.

Several other research firms have also issued reports on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

NYSE GSK opened at $33.59 on Monday. GSK has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market capitalization of $69.61 billion, a PE ratio of 21.81, a P/E/G ratio of 1.54 and a beta of 0.64. The company’s 50 day simple moving average is $36.08 and its 200 day simple moving average is $39.14.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently modified their holdings of the stock. DGS Capital Management LLC boosted its stake in shares of GSK by 3.9% during the 3rd quarter. DGS Capital Management LLC now owns 34,438 shares of the pharmaceutical company’s stock valued at $1,408,000 after buying an additional 1,304 shares during the period. Logan Capital Management Inc. boosted its stake in shares of GSK by 3.8% during the 3rd quarter. Logan Capital Management Inc. now owns 83,923 shares of the pharmaceutical company’s stock valued at $3,431,000 after buying an additional 3,083 shares during the period. Franklin Resources Inc. boosted its stake in shares of GSK by 8.6% during the 3rd quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company’s stock valued at $9,052,000 after buying an additional 18,539 shares during the period. Optimist Retirement Group LLC lifted its stake in shares of GSK by 3.7% in the 3rd quarter. Optimist Retirement Group LLC now owns 49,554 shares of the pharmaceutical company’s stock valued at $2,026,000 after purchasing an additional 1,790 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of GSK in the 3rd quarter valued at $787,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.00% of the company’s stock.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.68%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. GSK’s payout ratio is presently 98.70%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.